Fig. 3From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world settingBoxplots of the BA ratios over two years. Each box shows median, interquartile range and outliers for each BA ratio at baseline, year one and year twoBack to article page